Open Access
01.09.2015 | Seven-Day Profile Publication
Fluid challenges in intensive care: the FENICE study
A global inception cohort study
verfasst von:
Maurizio Cecconi, Christoph Hofer, Jean-Louis Teboul, Ville Pettila, Erika Wilkman, Zsolt Molnar, Giorgio Della Rocca, Cesar Aldecoa, Antonio Artigas, Sameer Jog, Michael Sander, Claudia Spies, Jean-Yves Lefrant, Daniel De Backer, on behalf of the FENICE Investigators and the ESICM Trial Group
Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC.
Methods
This was an observational study conducted in ICUs around the world. Each participating unit entered a maximum of 20 patients with one FC.
Results
2213 patients were enrolled and analyzed in the study. The median [interquartile range] amount of fluid given during an FC was 500 ml (500–1000). The median time was 24 min (40–60 min), and the median rate of FC was 1000 [500–1333] ml/h. The main indication for FC was hypotension in 1211 (59 %, CI 57–61 %). In 43 % (CI 41–45 %) of the cases no hemodynamic variable was used. Static markers of preload were used in 785 of 2213 cases (36 %, CI 34–37 %). Dynamic indices of preload responsiveness were used in 483 of 2213 cases (22 %, CI 20–24 %). No safety variable for the FC was used in 72 % (CI 70–74 %) of the cases. There was no statistically significant difference in the proportion of patients who received further fluids after the FC between those with a positive, with an uncertain or with a negatively judged response.
Conclusions
The current practice and evaluation of FC in critically ill patients are highly variable. Prediction of fluid responsiveness is not used routinely, safety limits are rarely used, and information from previous failed FCs is not always taken into account.
The online version of this article (doi:10.1007/s00134-015-3850-x) contains supplementary material, which is available to authorized users.
The FENICE investigators are listed in full in ESM 2 (National Coordinators) and ESM 4 (Steering Committee, Study Statistician, Study Coordinator and Local Investigators).
Many liters of intravenous fluids are used per year to treat critically ill patients worldwide. Fluids are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units (ICUs) [1]. The basic physiological target of administration of fluids is to improve tissue perfusion. Hemodynamic optimization with fluids has been shown to improve patient outcome when applied in the perioperative period and in the early phases of sepsis [1‐4]. Timing of the intervention is important; in the context of shock, higher fluid administration in the first 3 h was associated with better outcome in a retrospective study [5]. On the other hand, liberal administration of fluids may lead to a positive fluid balance [6] which is independently associated with a poor outcome [7]. Accordingly, in patients with respiratory failure, once hemodynamically stable, fluid restriction is associated with earlier weaning from mechanical ventilation [8].
Altogether, it seems reasonable to give the needed amount of fluids when hemodynamically patients are unstable and to restrict fluids when they are stabilized. Such an approach makes physiological sense and in theory should bring better outcomes to the patients. Whereas in overt bleeding, fluids are often given without guidance with specific hemodynamic monitoring, in other conditions, when hypovolemia may be subtler or when the response to fluids is more variable, fluids may be given on the basis of monitoring their hemodynamic impact. This practice, the “fluid challenge” technique (FC) was proposed more than 30 years ago [9‐11]. Over recent decades new techniques have been developed in order to monitor and predict the response to fluids. The roles of static markers of preload such as central venous pressure (CVP) and pulmonary artery occlusion pressure (PAOP) have been questioned and dynamic indices of preload have been studied [12‐14]. The use of dynamic indices is now recommended [4] but many technical limitations may preclude their use.
Anzeige
However, no data exist on the manner in which FCs are indicated and performed in critically ill patients around the globe. We conducted a multicenter international observational study aiming to evaluate the indications, current practice, and judgment of benefit of FCs in critical care settings. We hypothesized that there is an extensive variation in the current practice of FC.
Methods
This was an observational study conducted by the ESICM Trials Group (17–23 April 2013 or 23–29 May 2013) and registered on ClinicalTrials.Gov (NCT01787071). ICUs were able to enter the study in one of the 2 weeks. The possibility to choose between 2 weeks was chosen in order to compensate for differences in national holidays in different countries and therefore to maximize the recruitment of study units. IRB approval was obtained in each country and the local investigators were responsible to ensure that with local and national requirements were fulfilled. In most participating countries informed consent from the patient was waived owing to the observational study design. National coordinators and local investigators are listed in the electronic supplementary material (ESM).
We included all consecutive adult (18 years old and above) patients, up to a maximum of 20 per participating unit, in whom an FC was performed during a 1-week period. FC was defined as administration of any bolus of fluid (crystalloid or colloid) in less than 2 h. Administration of red blood cells or fresh frozen plasma was not considered as an FC. The exclusion criteria were previous inclusion in the study, overt bleeding, and time of an FC exceeding 120 min. Only one FC, ideally the first, was considered for each patient. Only one FC per patient was recorded.
We collected data on patient demographics, indications for the FC, the type, amount, and rate of fluids administered, available hemodynamic variables, and judgment on the efficacy and safety of the FC. The case report form (CRF) is available in the ESM. Anonymous CRF data were uploaded by local investigators using a Web-based electronic CRF (Clinfile, Sevres, France). The data were stored securely in a server located in Brussels. All procedures regarding data management complied with the EU directive on data protection (95/46/EC).
Anzeige
Study aims
The primary aim of this study was to evaluate how physicians indicate FC.
The secondary aims were
to evaluate the type, volume, and rate of fluid administered during an FC.
to evaluate variables used to trigger/indicate an FC, and to judge the effect or safety of an FC.
to compare the proportion of patients receiving further fluid administration based on the response to the fluid challenge, as judged by the bedside clinician after a fluid challenge.
Statistical analysis
Categorical variables are described as numbers (percentages) and continuous variables as mean (±standard deviation), if normally distributed, or median [interquartile range] if not normally distributed. The paired t test or Wilcoxon test was used to compare hemodynamic variables after the FC with baseline, when applicable. Proportions of patients were compared with χ2 test and data presented as proportions and odd ratios. A p value of less than 0.05 was considered statistically significant. We targeted a minimum of 100 study sites with a maximum of 20 FCs each and a minimum of 1000 patients.
Results
We included 2279 patients with an FC from 311 centers across 46 countries (ESM). Of those 2279, 66 patients were excluded from the analysis as a result of at least one exclusion criterion (see the study flow chart, Fig. 1 ESM). A total of 2213 patients were analyzed.
Data on demographic factors and concomitant treatment are presented in Table 1. The main diagnostic groups were sepsis (n = 595, 27.0 % [CI 25.2–28.9 %]), cardiac (n = 454, 20.6 % [CI 18.9–22.3 %]), and respiratory failure (n = 238, 10.8 % [CI 9.5–12.1 %]).
Table 1
Baseline characteristics and concomitant treatments in critically ill patients (N = 2213)
Age (years)
63 ± 16
Female sex
824 (37.3 [35.3–39.3])
Reason for admission to ICU [n (%)]
Medical
962 (43.5 [41.4–45.6])
Surgical
691 (31.2 [29.3–33.1])
Emergency surgical
548 (24.8 [23.0–26.6])
Main diagnosis
Sepsis
595 (27.0 [25.2–28.9])
Cardiac
454 (20.6 [18.9–22.3])
Respiratory
238 (10.8 [9.5–12.1])
Neurologic
180 (8.2 [7.1–9.3])
Trauma
141 (6.4 [5.4–7.4])
Intoxication
41 (1.9 [1.3–2.5])
Other
558 (25.3 [23.5–27.1])
SOFA score
7 [4–10]
Physiological variables
HR (bpm)
95 ± 24
MAP (mmHg)
70 ± 16
CVP (mmHg)
8 ± 5
Urine output (ml/h)
40 [20–80]
Fluid balance previous 24 h (ml)
2698 [1500–3945]
Lactate (mmol/L)
1.8 [1.1–2.9]
Vasopressor/inotropic agents
Dopamine (n (%); μg/kg min)
91 (4); 5 [4–10]
Norepinephrine (n (%); μg/kg min)
903 (41); 0.16 [0.07–0.34]
Epinephrine (n (%); μg/kg min)
74 (3); 0.1[0.03–0.30]
Dobutamine (n (%); μg/kg min)
159 (7); 4 [3–5]
Mechanical ventilation, n (%) of 2172
None
736 (33.8 [31.8–35.8])
Noninvasive ventilation
64 (2.9 [2.2–3.6])
Invasive mechanical ventilation
1372 (63.1 [61.1–65.1])
Characteristics of patients under invasive mechanical ventilation n (%) of 1372
Sedation present
927 (67.6 [65.1–70.1])
Spontaneous ventilation included
602 (43.8 [41.2–46.4])
Renal replacement therapy, n (%) of 2087
None
1930 (92.5 [91.4–93.6])
Dialysis
58 (2.8 [2.1–3.5])
Hemofiltration
99 (4.7 [3.8–5.6])
Qualitative data are given as absolute number (percentage); quantitative data are given as median value [interquartile range]
HR heart rate, MAP mean arterial pressure, CVP central venous pressure, CVVH continuous veno-venous hemofiltration
The median amount of fluid given during an FC was 500 ml [500–1000]. The median time was 24 min [40–60 min], and the median rate of fluid administration was 1000 [500–1333] ml/h. Crystalloids were the most used (in 74.0 % [CI 72.2–75.8 %] of the cases) including normal saline in 45.9 % [CI 25.2–28.9 %], and balanced solutions were used in 53.5 % [CI 51.4–55.6 %] of FCs (Table 2).
Table 2
Fluid challenge (N = 2213) characteristics
Volume (ml), median [IQR]
500 [500–999]
Rate (ml/h), median [IQR]
1000 [500–1333]
Type of fluids
n
% Of category
% All fluids
Crystalloids
1713
74.3 [72.5–76.1]
NaCl 0.9 %
786
45.9 [43.5–48.3]
34.1 [32.1–36.1]
Balanced
916
53.5 [51.1–55.9]
39.8 [37.8–41.8]
G5 % DW
4
0.2 [0.0–0.4]
0.2 [0.0–0.4]
G5 % NaCl 0.45 %
7
0.4 [0.1–0.7]
0.3 [0.1–0.5]
Colloids
591
25.6 [23.8–27.4]
HES
249
42.1 [38.1–46.1]
10.8 [9.5–12.1]
Albumin 4–5 %
101
17.1 [14.1–20.1]
4.3 [3.5–5.2]
Gelatin
203
34.3 [30.5–38.1]
8.8 [7.6–10.0]
Dextran
13
2.2 [1.0–3.4]
0.5 [0.2–0.8]
Albumin 20 %
25
4.2 [2.6–5.8]
1.1 [0.7–1.5]
NaCl saline, balanced crystalloids with chloride concentration lower than saline (i.e., Plasma Lyte, Hartman’s), G5 % glucose 5 %, DW dextrose in water, HES hydroxyethyl starch
The main indication for fluid administration was hypotension in 1211 (58.7 % [CI 56.7–60.1 %]) of FCs. In 42.7 % [CI 40.6–44.8 %] of the cases no hemodynamic variable was used to predict fluid responsiveness. Static markers of preload were used in 785 of 2213 cases (35.5 % [CI 33.5–37.5 %]). In 572 of 785 of these cases (89.9 % [CI 87.8–92.0 %]) CVP was the leading variable used (25.8 % [CI 24.0–27.6 %] of all FCs). Dynamic indices of preload responsiveness were used in 483 of 2213 cases (21.9 % [CI 20.2–23.6 %]). In 238 of those 483 cases (49.3 % [CI 44.8–53.8 %]) passive leg raising (PLR) was the leading variable (10.7 % [CI 9.4–12.0 %] of all FCs) (Table 3).
Table 3
Indications and variables used to predict fluid responsiveness (N = 2213)
Indication
n (%)
Hypotension
1211 (58.7 [56.7–60.8])
Weaning vasopressor
146 (7.1 [6.0–8.2])
Cardiac output
62 (3.0) [2.3–3.7]
Oliguria
372 (18.0 [16.4–19.6])
Skin mottling
36 (1.7 [1.2–2.2])
Lactate
128 (6.2 [5.2–7.2])
SvO2/ScvO2
10 (0.5 [0.2–0.8])
SVV/PPV
37 (1.8 [1.3–2.4])
CVP/PAOP
60 (2.9 [2.2–3.6])
Hemodynamic variable used to predict fluid responsiveness
n
% Of category
% All
No variable used
945
42.7 [40.6–44.8]
Any variable used
1268
57.3 [55.2–59.4]
Static
785
35.5 [33.5–37.5]
CVP
572
89.9 [87.8–92.0]
25.8 [24.0–27.6]
PAOP
31
4.9 [3.4–6.4]
1.4 [0.9–1.9]
GEDVI
33
5.2 [3.6–6.8]
1.5 [1.0–2.0]
Other
149
23.4 [20.4–26.4]
6.7 [5.7–7.8]
Dynamic
483
21.9 [20.2–23.6]
PPV
88
18.2 [14.8–21.6]
4.0 [3.2–4.8]
SVV
88
18.2 [14.8–21.6]
4.0 [3.2–4.8]
PPV + SVV
24
5.0 [3.1–6.9]
1.1 [0.7–1.5]
PLR
238
49.3 [44.8–53.8]
10.7 [9.4–12.0]
Echo variables
45
9.3 [6.7–11.9]
2.0 [1.4–2.6]
SvO2 mixed venous oxygen saturation, ScvO2 central venous oxygen saturation, SVV stroke volume variation, PPV pulse pressure variation, CVP central venous pressure, PAOP pulmonary artery occlusion pressure, GEDVI global end diastolic volume, PLR passive leg raising, Echo echocardiography
The response to fluid administration was judged as positive in 1544 of 2213 (69.8 % [CI 67.9–71.7 %]) of the FCs, most often as an increase in arterial blood pressure (1039 of 1544, 67.3 % [CI 65.0–69.7 %]). No safety variable for the FC was used in 72.0 % [CI 70.1–73.9 %] of the cases. When used, CVP was the most common variable (57 %). Further fluids were administered in 1050 of 2213 (49.8 % [CI 47.7–51.9 %]) of the cases. The proportion of patients who received further fluids after was similar in patients with a positive (47.9 ± 2.5 %), with an uncertain [52.4 ± 7.1 %, OR 0.94 (0.76–1.16)] or with a negatively judged response to FC [49.4 ± 6.6 %, OR 0.83 (0.62–1.13)] (p = 0.46 by χ2 test) (Fig. 1).
×
Anzeige
Discussion
The two major findings of this large global multicenter observational study comprising 2213 patients are first a significant variability in the conduction of FC and second the fact that the response to the initial FC does not have an impact when prescribing further fluid administration. These findings were observed in critically ill patients all around the world. All aspects of the FC, the type, volume, and rate of given fluids, and more importantly the indication, evaluation of possible benefit, and safety variables used varied significantly. It is possible that some of the variability may be explained by variables not collected in our study, such as unit policies and protocols.
While we recorded only one FC per patient, we also recorded the decision for further fluid administration post FC. When looking at the response to fluid administration, investigators found a positive response only in seven cases out of ten. However, further fluids were given in comparable proportions of patients despite the initial response. If an FC is used to look at a dynamic response and to decide whether further fluids may be administered safely, one would expect that further fluids should be administered only in patients with a positive initial response. In our study the response to the initial fluid challenge made no difference to the decision for further fluid administration. This behavior seems to be harmful and highlights a huge need for education.
This huge variability in the current practice regarding an FC may reflect the presence of controversies in current guidelines. In the Surviving Sepsis Guidelines fluids are recommended in the very early phase of hemodynamic resuscitation of patients with severe sepsis [15]. In this case a fluid bolus is considered as administration of fluids of 30 ml/kg. In high-risk surgical patients fluid challenges are often given in smaller amounts [11]. In the perioperative setting there are guidelines covering the administration of fluids recommending the use of fluids for stroke volume optimization [16]. While it is true that different conditions may require different techniques, our data show extensive variability even within the same clinical condition.
Simple clinical signs led to FC in more than 80 % patients (hypotension, 58.7 %; oliguria, 18 %; or weaning of vasopressors, 7.1 %). Of note, markers of inadequate tissue perfusion such as lactate or skin mottling were used as an indication for an FC only in less than 8 % of the cases. This seems paradoxical since fluids are mostly indicated to increase cardiac output [11, 17, 18] and tissue perfusion [19]. Moreover, some studies focused on microcirculation clearly showed that clinical signs cannot predict microcirculatory impairment [20] and that improving MAP and diuresis is not sufficient for improving patient outcome [21‐23].
Anzeige
These findings are in line with the ones published by Boulain and coauthors [24]. In their study, limited to ICUs in France, low blood pressure and low urine output were the most used triggers for fluid administration. The wider scope of our study demonstrates that this is common practice around the globe. It is interesting that so much attention is paid to the blood pressure at the bedside. This variable is the most used both for triggering and assessing the response to an FC. It is possible that the goal of many clinicians is the one of increasing BP with an FC. On the other hand it is possible that arterial blood pressure was used as a surrogate of cardiac output (CO). This seems common practice despite the known limitations of this variable when used to estimate CO. The increase in arterial pressure during an FC for instance is variable and depends on vascular tone and arterial elastance [25]. In patients increasing their CO in response to fluids, arterial blood pressure increases only in those with high arterial elastance [26, 27]. In summary, while fluids are mostly indicated to increase cardiac output [11, 17, 18] and tissue perfusion [19] and not to just to increase blood pressure, at the bedside clinicians rely heavily on this variable both to predict and assess fluid responsiveness (Table 4).
Table 4
Judged response to fluid challenge
Response classification [no. (%) of 2162]
Negative response
429 (19.8 [18.1–21.5])
Positive response
1544 (71.4 [69.5–71.4])
Uncertain
189 (8.7 [7.5–9.9])
Variable use to evaluate response [no. (%) of 1544 with positive response]
Increase in BP
1039 (67.3 [65.0–69.7])
Decrease vasopressors
56 (3.6 [2.7–4.5])
Increase in CO
174 (11.3 [9.7–12.9])
Increase in SV
100 (6.5 [5.3–7.7])
Decrease in HR
374 (24.2 [22.1–26.3])
Urine output
590 (38.2 [35.8–40.6])
Lactate
281 (18.2 [16.3–20.1])
Skin perfusion
128 (8.3 [6.9–9.7])
Mental state
40 (2.6 [1.8–3.4])
ScvO2/SvO2
77 (5.0 [3.9–6.1])
SVV/PPV
110 (7.1 [5.8–8.4])
CVP/PAOP
256 (16.6 [14.7–18.5])
Other
132 (8.5 [7.1–9.9])
Safety limit used [no. (%) of 2213]
577 (27.9 [25.7–30.1])
Variable used in the safety limit group [no. (%) of 577]
CVP
329 (57.0 [53.0–61.0])
PAOP
39 (6.7 [4.7–8.8])
GEDVI
11 (1.9 [4.7–8.8])
EVLWI
28 (4.9 [3.1–6.7])
SpO2/SaO2
105 (18.2 [15.1–21.35])
CO
8 (1.4 [0.4–2.4])
SVV/PPV
80 (13.9 [11.1–16.7])
Other
120 (20.8 [17.5–24.1])
BP blood pressure, CO cardiac output, SV stroke volume, HR heart rate, SvO2 mixed venous oxygen saturation, ScvO2 central venous oxygen saturation, SVV stroke volume variation, PPV pulse pressure variation, CVP central venous pressure, PAOP pulmonary artery occlusion pressure, GEDVI global end diastolic volume, EVLWI extravascular lung water index
Importantly, in almost half of the patients no hemodynamic variable was used to predict fluid responsiveness—and if used CVP was used most often. This is interesting considering that the CVP is a poor variable to predict fluid responsiveness [12, 14, 28].
The use of dynamic indices of preload was infrequent in our study. Cyclical changes in stroke volume (stroke volume variation, SVV) and pulse pressure (pulse pressure variation, PPV) during mechanical ventilation have been shown to predict fluid responsiveness with high sensitivity and specificity [29]. However, one of the limitations is that the patient has to be in controlled ventilation with tidal volumes equal to or higher than 8 ml/kg of ideal body weight [30], and with no arrhythmias. It is possible that the limited use of these three dynamic indices (in total 9 % of patients) was influenced by a high prevalence of patients with preserved spontaneous breathing activity. Another possible explanation is that we encouraged investigators to look at the first fluid challenge in our study. In this case flow monitors may have not have been in place yet. In this scenario though, we would have expected a more prevalent use of echocardiography. Of note, this was used to indicate FC in only 2 % of the patients.
Passive leg rising is a maneuver that produces an autologous fluid challenge by shifting venous blood from the legs to the intrathoracic compartment. The response measured by a flow monitor is able to predict the response to a fluid challenge. This has been studied and validated with different flow monitors. With a lower degree of accuracy with respect to cardiac output and stroke volume, blood pressure monitoring could be used for this technique, too [31]. Considering that an increase in blood pressure was used as the positive indicator of a fluid challenge in two-thirds of the cases, our data suggest that arterial pressure is the hemodynamic variable on which the majority of clinicians focus. Hypotension and weaning of vasopressor were the main indications to give an FC and the response in arterial pressure was the most used one for evaluation of possible benefit.
Anzeige
Our findings highlight a possible safety problem. Half of the patients with a negative response received further fluids. Of note, in three out four cases no safety limits were used at all. While CVP is a poor marker of preload and fluid responsiveness, it is one of the regulating functions of the venous return and a raise in CVP may be used as a safety limit [9, 32‐34]. Given this finding and that patients received further fluids despite no response to the initial FC, the current practice and evaluation of FC and fluid administration in critically ill patients seems to be arbitrary, not evidence-based and possibly harmful.
We also found a high variability in the type of fluid used with higher use of crystalloids compared to colloids. It is difficult to interpret these results, since this study was performed during a time of high debate among intensive care clinicians following the publication of large randomized controlled trials advocating the use of crystalloids versus colloids [1, 35‐38].
Our study has some obvious strengths. First, to the best of our knowledge this study is the largest prospective observational study investigating FCs in critically ill patients and thus provides a reasonably exact estimate of the current practice of the FCs given. Second, the international multicenter design limiting the cases from individual sites increases its external validity. However, there are several limitations of our study to be considered. First, we recorded only when FCs were given and not when FCs were not given. Thus, in practice we may have underestimated the times when variables used to predict fluid responsiveness were used. Second, we encouraged investigators to record data on the first fluid challenge, which may have several implications. At early stages, a positive response to fluids is more likely and patients are often less invasively monitored. Studying patients at later stages may have yielded different results. Third, we allowed a wide range of options (volume, type of fluid, first or subsequent FC) to be recorded during an FC. It is possible that some investigators considered an FC what would be normally defined a more sustained volume expansion.
We conclude that the current practice and evaluation of FC in critically ill patients seems to be arbitrary. While not demonstrable in this observational study, this practice does not seem evidence-based and could be harmful.
Our findings highlight an urgent need for more educational activities and more research to assess whether a more standardized approach to a fluid challenge could lead to better patient-centered outcomes.
Conflicts of interest
Antonio Artigas is a scientific advisor of B. Braun and Ferrer, received a restricted research grant from Grifols and Pulsion, and is an invited speaker of Grifols. Michael Sander received financial support from Masimo, Pulsion, Edwards Lifesciences, and Maquet. Jean-Louis Teboul is a member of the medical advisory board of Pulsion. The other authors declare no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Anästhesiologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes AINS, den Premium-Inhalten der AINS-Fachzeitschriften, inklusive einer gedruckten AINS-Zeitschrift Ihrer Wahl.
Fluid challenges in intensive care: the FENICE study A global inception cohort study
verfasst von
Maurizio Cecconi Christoph Hofer Jean-Louis Teboul Ville Pettila Erika Wilkman Zsolt Molnar Giorgio Della Rocca Cesar Aldecoa Antonio Artigas Sameer Jog Michael Sander Claudia Spies Jean-Yves Lefrant Daniel De Backer on behalf of the FENICE Investigators and the ESICM Trial Group
Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.
Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.
Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.
Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.
Update AINS
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.